C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study

BACKGROUND: Poor response to anti-tumour necrosis factor biologicals like infliximab (IFX) is observed in patients with ulcerative colitis (UC), which may lead to prolonged morbidity and waste of medical resources. We aimed to look for potential biomarkers of response to IFX in patients with UC who...

Full description

Saved in:
Bibliographic Details
Published in:BMC Gastroenterol
Main Authors: Iwasa, Ryota, Yamada, Akihiro, Sono, Koji, Furukawa, Ryuichi, Takeuchi, Ken, Suzuki, Yasuo
Format: Artigo
Language:Inglês
Published: BioMed Central 2015
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4535387/
https://ncbi.nlm.nih.gov/pubmed/26271624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0333-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items